阿霉素肾病动物模型的研究进展

摘要
图/表
参考文献
相关文章 (5)

\[1\]Sternberg SS. Crossstriated fibrils and other ultrastructural alterations in glomeruli of rats with daunomycin nephrosis\[J\]. Lab Invest, 1970, 23(1): 39-51.
\[2\]Bucciarelli E, Binazzi R, Santori P, et al. Nephrotic syndrome in rats due to adriamycin chlorhydrate\[J\]. Lav Ist Anat Istol Patol Univ Studi Perugia, 1976, 36(2): 53-69
\[3\]Chen A,Sheu LF, Ho YS, et al. Experimental focal segmental glomerulosclerosis in mice\[J\]. Nephron, 1998, 78（4）: 440-452.
\[4\]Burke JJ, Laucius JF, Brodovsky HS, et al. Doxorubicin hydrochloride-associated renal failure\[J\]. Arch Intern Med, 1977, 137（3）: 385-388.
\[5\]Pippin JW, Brinkkoetter PT, CormackAboud FC, et al. Inducible rodent models of acquired podocyte diseases\[J\]. Am J Physiol Renal Physiol, 2009, 296(2): F213-F229.
\[6\]Weiss RB. The anthracyclines: will we ever find a better doxorubicin\[J\]? Semin Oncol, 1992, 19（6）: 670-686.
\[7\]De Mik SM, Hoogduijn MJ, de Bruin RW, et al. Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models\[J\]. BMC Nephrol, 2013, 14: 74.
\[8\]Takiue K, Sugiyama H, Inoue T, et al. Acatalasemic mice are mildly susceptible to adriamycin nephropathy and exhibit increased albuminuria and glomerulosclerosis\[J\]. BMC Nephrol, 2012, 13: 14.
\[9\]Takanashi S, Bachur NR. Adriamycin metabolism in man. Evidence from urinary metabolites\[J\]. Drug Metab Dispos, 1976, 4(1): 79-87.
\[10\]Yesair DW, Schwartzbach E, Shuck D, et al. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species\[J\]. Cancer Res, 1972, 32（6）: 1177-1183.
\[11\]Cao Q, Wang Y, Zheng D, et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis\[J\]. J Am Soc Nephrol, 2010, 21（6）: 933-942.
\[12\]Lee VW, Wang Y, Qin X, et al. Adriamycin nephropathy in severe combined immunodeficient (SCID) mice\[J\]. Nephrol Dial Transplant, 2006, 21(11): 3293-3298.
\[13\]Jeansson M, Bjorck K, Tenstad O, et al. Adriamycin alters glomerular endothelium to induce proteinuria\[J\]. J Am Soc Nephrol, 2009, 20（1）: 114-122.
\[14\]Hayashi K, Sasamura H, Ishiguro K, et al. Regression of glomerulosclerosis in response to transient treatment with angiotensin Ⅱ blockers is attenuated by blockade of matrix metalloproteinase2\[J\]. Kidney Int, 2010, 78（1）: 69-78.
\[15\]Heikkil E, Juhila J, Lassila M, et al. β-Catenin mediates adriamycin-induced albuminuria and podocyte injury in the adult mouse kidneys\[J\]. Nephrol Dial Transplant, 2010, 25(8): 2437-2446.
\[16\]Deelman LE, Navis G, de Boer E, et al. Role of proteinuria in the regulation of renal renin-angiotensin system components in unilateral proteinuric rats\[J\]. J Renin Angiotensin Aldosterone Syst, 2003, 4(1): 38-42.
\[17\]Mandelbaum A, Podjarny E, Bernheim J, et al. Role of thromboxane in the altered vascular reactivity of pregnant rats with adriamycin nephropathy\[J\]. Nephrol Dial Transplant, 1999, 14(5): 1124-1128.
\[18\]Cheng H, Fan X, Guan Y, et al. Distinct roles for basal and induced COX-2 in podocyte injury\[J\]. J Am Soc Nephrol, 2009, 20(9): 1953-1962.
\[19\]Rangan GK, Wang Y, Harris DC. Induction of proteinuric chronic glomerular disease in the rat (Rattus norvegicus) by intracardiac injection of doxorubicin hydrochloride\[J\]. Contemp Top Lab Anim Sci, 2001, 40(5): 44-49.
\[20\]Porpaczy P, Schmidbauer CP, Georgopoulos A, et al. Concentrations of doxorubicin in renal interstitial fluid after peripheral intravenous and intrarenal artery infusion in dogs\[J\]. J Urol, 1984, 131（1）: 169-172.
\[21\]Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse\[J\]. Cancer Chemother Pharmacol, 1981, 5（4）: 267-270.
\[22\]De Boer E, Navis G, Tiebosch AT, et al. Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats\[J\]. J Am Soc Nephrol, 1999, 10(11): 2359-2366.
\[23\]Ochodnicky P, Henning RH, Buikema H, et al. Renal endothelial function and blood flow predict the individual susceptibility to adriamycininduced renal damage\[J\]. Nephrol Dial Transplant, 2009, 24(2): 413-420.
\[24\]Sakemi T, Ohtsuka N, Tomiyoshi Y, et al. Sex difference in progression of adriamycin-induced nephropathy in rats\[J\]. Am J Nephrol, 1996, 16（6）: 540-547.
\[25\]Wang Y, Wang YP, Tay YC, et al. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events\[J\]. Kidney Int, 2000, 58(4): 1797-1804.
\[26\]Zheng Z, SchmidtOtt KM, Chua S, et al. A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse\[J\]. Proc Natl Acad Sci USA, 2005, 102(7): 2502-2507.
\[27\]Zheng Z. An ancestral haplotype defines susceptibility to doxorubicin nephropathy in the laboratory mouse\[J\]. J Am Soc Nephrol, 2006, 17(7): 1796-1800.
\[28\]Kastner S, Fels LM, KoobEmunds L, et al. Effects of adriamycin on the balance of glomerular protein metabolism: studies in isolated glomeruli of the atlantic hagfish, myxine glutinosa\[J\]. Cell Physiol Biochem, 1995, 5(6): 399-407
\[29\]Barbey MM, Fels LM, Soose M, et al. Adriamycin affects glomerular renal function: evidence for the involvement of oxygen radicals\[J\]. Free Radic Res Commun, 1989, 7(3/6): 195-203.
\[30\]Guo J, Ananthakrishnan R, Qu W, et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis\[J\]. J Am Soc Nephrol, 2008, 19（5）: 961-972.